09:45 ET -- Eli Lilly is one of the most mentioned companies in the U.S. across all news items in the last 12 hours, according to Factiva data. Eli Lilly said Tuesday it is paying $48 a share of DICE Therapeutics to buy the smaller biopharmaceutical company for $2.4 billion, which would represent a premium of about 40% to DICE's 30-day volume-weighted average trading price up to its last trading day on Friday. The transaction is expected to close in the third quarter of this year. Dow Jones & Co. owns Factiva. (chris.wack@wsj.com)

(END) Dow Jones Newswires

June 20, 2023 10:00 ET (14:00 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.
DICE Therapeutics (NASDAQ:DICE)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more DICE Therapeutics Charts.
DICE Therapeutics (NASDAQ:DICE)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more DICE Therapeutics Charts.